<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2915">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906863</url>
  </required_header>
  <id_info>
    <org_study_id>AAAQ9793</org_study_id>
    <secondary_id>1RF1AG054080-01</secondary_id>
    <nct_id>NCT04906863</nct_id>
  </id_info>
  <brief_title>Genetic Studies of Early-onset Dementia</brief_title>
  <official_title>Genetic Studies of Early-onset Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to identify genetic factors that contribute to risk and progression&#xD;
      of early-onset dementia (loss of memory function before the age of 70 years) across all&#xD;
      ethnic groups, including Alzheimer's Disease, mild cognitive impairment and other dementias.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population includes individuals affected by Alzheimer's Disease, mild cognitive&#xD;
      impairment, other dementias, cognitively healthy individuals without memory problems, or&#xD;
      their family members.&#xD;
&#xD;
      Ascertainment is across both males and females, and all race and ethnic groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic risk variants associated with early-onset dementia</measure>
    <time_frame>2 years</time_frame>
    <description>Genetic factors will be measured through genome-wide genotyping arrays and/or whole-genome sequencing, and then correlated with Alzheimer disease and related phenotypes, such as cognitive impairment, functional impairment, and relevant biomarkers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in blood biomarkers in early-onset dementia</measure>
    <time_frame>2 years</time_frame>
    <description>Blood biomarkers including plasma amyloid beta and tau protein will be assessed in blood and correlated with onset and progression of memory loss and functional impairment</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Dementia, Early Onset</condition>
  <arm_group>
    <arm_group_label>Mild Cognitive Impairment</arm_group_label>
    <description>Individuals with mild cognitive impairment that began before age 70</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dementia/Alzheimer's Disease</arm_group_label>
    <description>Individuals with Alzheimer's Disease or other dementia that began before age 70</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitively Healthy</arm_group_label>
    <description>Cognitively healthy individuals over the age of 30 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>Blood draw for identification of genetic variants associated with the development of memory problems</description>
    <arm_group_label>Cognitively Healthy</arm_group_label>
    <arm_group_label>Dementia/Alzheimer's Disease</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurocognitive testing</intervention_name>
    <description>Brief memory test</description>
    <arm_group_label>Cognitively Healthy</arm_group_label>
    <arm_group_label>Dementia/Alzheimer's Disease</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical questionnaire</intervention_name>
    <description>Collection of medical history</description>
    <arm_group_label>Cognitively Healthy</arm_group_label>
    <arm_group_label>Dementia/Alzheimer's Disease</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Approximately 40ml of blood and/or saliva&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of individuals affected by dementia, mild cognitive&#xD;
        impairment, cognitively healthy individuals, or their family members. Ascertainment is&#xD;
        across both males and females, and all race-ethnic groups.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  18 years and older&#xD;
&#xD;
          -  Individuals diagnosed with dementia, their family members and unrelated healthy&#xD;
             controls without dementia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -Individuals with competing diagnosis such as Huntington's disease, traumatic brain injury,&#xD;
        drug or alcohol abuse, or schizophrenia, etc., unless family members of a dementia affected&#xD;
        individual&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christiane Reitz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Penelope Baez Sarita</last_name>
    <phone>212-305-1527</phone>
    <email>pib2102@cumc.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penelope Baez Sarita, MD</last_name>
      <phone>212-305-1527</phone>
      <email>pib2102@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Christiane Reitz, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Christiane Reitz, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Neurology and Epidemiology</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Memory loss</keyword>
  <keyword>Early-onset Alzheimer's disease</keyword>
  <keyword>Mild cognitive impairment</keyword>
  <keyword>Normal cognition</keyword>
  <keyword>Dementia</keyword>
  <keyword>Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data from this study will be shared via government required repositories and with our collaborators. Data are coded, with no personally identifiable information included. Data shared include the genomic data (array data, sequence data, APOE genotyping results, etc), phenotype data (case/control status, age of onset, etc), and basic demographic information (sex, race/ethnicity data if available, etc).&#xD;
The NIH Genomic Data Sharing Policy (GDS Policy) took effect on January 25th, 2015. This necessitates that we send coded data and samples to the National Institute on Aging Genetics of Alzheimer's Disease (NIAGADS)l; in some cases materials derived from participants (blood or DNA) may be stored at the National Cell Repository for Alzheimer's Disease (NCRAD).&#xD;
We may share deidentified genomic and phenotypic data with collaborators at other sites in order the accomplish the scientific aims of the study. Such research is performed with the approval of the local internal review boards.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>This study adheres to the NIA Alzheimer Disease Genomics Data Sharing Plan (https://www.nia.nih.gov/research/dn/alzheimers-disease-genomics-sharing-plan). As such, genomic data will be deposited in NIH/NIA data repositories (www.niagads.org). For genomic data, this typically happens within a year of data generation, or upon publication in scientific journals (whichever is sooner). Basic phenotypic data (affection status, age of onset, sex, family structure if applicable, etc) are deposited with the genomic data. More detailed phenotypic data (cognitive data, biomarker, etc) will be made available upon publication. Data dictionaries for primary data (genomic data and basic phenotypic data) will be available with the deposition of data into the NIH/NIA data repositories (www.niagads.org). Additional supporting documentation (analysis plans, study protocols, etc) is typically described in detail upon publication of results in peer reviewed literature.</ipd_time_frame>
    <ipd_access_criteria>This study adheres to the NIA Alzheimer disease Genomics Data Sharing Plan (https://www.nia.nih.gov/research/dn/alzheimers-disease-genomics-sharing-plan). As part of this plan data distribution agreements are required before recipients receive any data from this study. The primary requirements for the DDA include language ensuring that (1) data are not transferred to others beyond the initial recipient, (2) no attempt will be made to identify participants, (3) any results or data generated as part of the study will be shared back to NIA/NIAGADS. See the NIA Data Distribution Agreement for more details (https://www.niagads.org/sites/all/public_files/NIAGADS-DDA.pdf).</ipd_access_criteria>
    <ipd_url>https://www.nia.nih.gov/research/dn/alzheimers-disease-genomics-sharing-plan</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

